Several agonist antibodies targeting either DR4 or DR5 are currently in clinical development.26 Therefore, we next assessed the impact of antagonistic antibodies directed against DR4 or DR5 on the viability of myeloid leukemia cells treated with the Med+TRAIL combination. This evidence concerns the gene TNFRSF10B and myeloid leukemia.